4726 studies found for:    leukemia
Show Display Options
Rank Status Study
1 Active, not recruiting Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)
Conditions: B-cell Chronic Lymphocytic Leukemia;   Hematopoietic/Lymphoid Cancer;   Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia
Interventions: Drug: carfilzomib;   Other: Cytokine Assessment;   Other: Pharmacodynamic Studies;   Other: Proteosome Inhibition Assessment;   Other: Pharmacogenomic Studies
2 Terminated Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Conditions: Minimal Residual Disease;   Leukemia, Lymphoblastic, Acute;   Leukemia, Myelogenous, Acute
Interventions: Drug: Clofarabine;   Drug: Cytarabine;   Drug: Methotrexate
3 Completed Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Myeloid Leukemia in Remission;   Chronic Phase Chronic Myelogenous Leukemia;   Previously Treated Myelodysplastic Syndromes;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Relapsing Chronic Myelogenous Leukemia
Interventions: Biological: PR1 leukemia peptide vaccine;   Drug: Montanide ISA 51 VG;   Biological: sargramostim;   Other: laboratory biomarker analysis
4 Active, not recruiting Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Blastic Phase Chronic Myelogenous Leukemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Secondary Acute Myeloid Leukemia;   Splenic Marginal Zone Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: vorinostat;   Drug: decitabine
5 Completed Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Basophilic Leukemia;   Adult Acute Eosinophilic Leukemia;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Blastic Phase Chronic Myelogenous Leukemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts in Transformation;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes
Interventions: Drug: tanespimycin;   Drug: cytarabine
6 Recruiting Relationship Between Natural Killer Cells' Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2
Condition: Leukemia
Interventions: Other: flow cytometry;   Other: immunologic technique;   Other: laboratory biomarker analysis
7 Completed Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia
Conditions: Acute Myelogenous Leukemia;   Myelodysplasia
Intervention: Biological: autologous tumor cells
8 Recruiting Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia
Conditions: Relapsed Acute Lymphoblastic Leukemia;   Relapsed Acute Myelogenous Leukemia
Intervention: Drug: GNKG168
9 Active, not recruiting Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia;   Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: nilotinib;   Drug: imatinib mesylate;   Other: pharmacological study
10 Completed Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
Conditions: Adult Acute Basophilic Leukemia;   Adult Acute Eosinophilic Leukemia;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: sorafenib tosylate;   Other: pharmacological study;   Other: laboratory biomarker analysis
11 Unknown  Multi-center Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia;   CLL
Interventions: Drug: Revlimid, rituximab;   Drug: Relapsed or refractory CLL. Lenalidomide and Rituximab
12 Completed Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia
Conditions: Chronic Myelomonocytic Leukemia;   Chronic Myelogenous Leukemia
Intervention: Drug: Imatinib
13 Terminated
Has Results
Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
Condition: Leukemia
Interventions: Biological: bcr-abl peptide vaccine;   Genetic: reverse transcriptase-polymerase chain reaction
14 Active, not recruiting Direct Measurement of Leukemic Cell Turnover (Synthesis and Removal) in Patients With Chronic Lymphocytic Leukemia (CLL) Using Deuterated Water
Condition: Chronic Lymphocytic Leukemia
Intervention:
15 Unknown  Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia
Conditions: Leukemias;   Acute Myeloid Leukemia (AML);   Acute Lymphocytic Leukemia (ALL);   Adult T Cell Leukemia (ATL);   Chronic Myeloid Leukemia (CML-BP);   Chronic Lymphocytic Leukemia (CLL);   Myelodysplastic Syndrome (MDS);   Chronic Myelomonocytic Leukemia (CMML)
Intervention: Drug: Terameprocol (EM-1421)
16 Completed
Has Results
Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia
Conditions: Large Granular Lymphocytic Leukemia;   LGL Leukemia
Interventions: Drug: Cyclosporine;   Genetic: Gene expression analysis;   Genetic: Microarray analysis;   Other: Laboratory biomarker analysis
17 Recruiting Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia;   Chronic Lymphocytic Leukemia
Intervention: Drug: SG2000
18 Completed DNA Analysis of Bone Marrow and Blood Samples From Young Patients With Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Condition: Leukemia
Interventions: Genetic: Southern blotting;   Genetic: chromosomal translocation analysis;   Genetic: cytogenetic analysis;   Genetic: gene rearrangement analysis;   Genetic: mutation analysis
19 Completed Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Condition: Leukemia
Intervention: Drug: gemcitabine hydrochloride
20 Terminated Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation
Conditions: Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndrome-Refractory Anemia With Excess Blasts
Intervention: Biological: GM-K562/leukemia cell vaccine

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years